Sung Mike R, Tomasini Pascale, Le Lisa W, Kamel-Reid Suzanne, Tsao Ming-Sound, Liu Geoffrey, Bradbury Penelope A, Shepherd Frances A, Li Janice J N, Feld Ronald, Leighl Natasha B
Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
JTO Clin Res Rep. 2021 Dec 4;3(2):100259. doi: 10.1016/j.jtocrr.2021.100259. eCollection 2022 Feb.
In addition to the higher prevalence of mutations found among lung cancer cases in East Asian patients, it is unclear whether there are differences in treatment outcomes by ethnicity-that is, East Asian versus non-East Asian.
Patients diagnosed with EGFR-mutant lung cancer between January 2004 and October 2014 at a single center were reviewed. Data captured included demographics, tumor and treatment information, and survival. Survival of patients of East Asian and non-East Asian ancestry was compared, including in the subgroup that received EGFR tyrosine kinase inhibitor (TKI) for advanced disease and in those with early-stage disease that underwent surgical resection.
A total of 348 patients with EGFR-mutant NSCLC were identified. There was a higher proportion of nonsmokers among those of East Asian ethnicity. No significant difference in survival was seen between patients of East Asian and non-East Asian ethnicity, median 6.7 years (95% confidence interval [CI]: 5.4-not applicable) and 5.4 years (95% CI: 4.1-7.2), respectively ( = 0.09). Among 196 patients that received treatment with EGFR TKI, the median survival from TKI initiation was also similar for those of East Asian and non-East Asian ethnicity, 3.0 years (95% CI: 2.1-3.5) and 2.7 years (95% CI: 2.2-3.5), respectively. Among the early-stage patients that underwent surgical resection (n = 163), those of East Asian ethnicity had similar median recurrence-free survival from surgery compared with non-East Asian patients, 5.3 years (95% CI: 3.5-not applicable) and 5.1 years (95% CI: 3.3-7.2), respectively.
In a cohort of patients with EGFR-mutant lung cancer with access to uniform standards of care, East Asian ethnicity was not associated with improved survival after treatment with EGFR TKI or surgical resection.
除了东亚患者肺癌病例中发现的突变患病率较高外，目前尚不清楚不同种族（即东亚与非东亚）的治疗结果是否存在差异。
回顾了2004年1月至2014年10月在单一中心诊断为表皮生长因子受体（EGFR）突变型肺癌的患者。收集的数据包括人口统计学、肿瘤和治疗信息以及生存率。比较了东亚和非东亚血统患者的生存率，包括接受EGFR酪氨酸激酶抑制剂（TKI）治疗晚期疾病的亚组以及接受手术切除的早期疾病患者。
共识别出348例EGFR突变型非小细胞肺癌患者。东亚种族患者中不吸烟者的比例较高。东亚和非东亚种族患者的生存率无显著差异，中位生存期分别为6.7年（95%置信区间[CI]：5.4 - 不适用）和5.4年（95%CI：4.1 - 7.2）（P = 0.09）。在196例接受EGFR TKI治疗的患者中，东亚和非东亚种族患者从开始使用TKI起的中位生存期也相似，分别为3.0年（95%CI：2.1 - 3.5）和2.7年（95%CI：2.2 - 3.5）。在接受手术切除的早期患者（n = 163）中，东亚种族患者与非东亚患者相比，术后无复发生存期的中位数相似，分别为5.3年（95%CI：3.5 - 不适用）和5.1年（95%CI：3.3 - 7.2）。
在一组接受统一护理标准的EGFR突变型肺癌患者中，东亚种族与EGFR TKI治疗或手术切除后的生存率提高无关。
